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Abstract
HTLV-1 infection is associated with several inflammatory disorders, including the neurodegenerative condition HTLV-1-
associated myelopathy/tropical spastic paraparesis (HAM/TSP). It is unclear why a minority of infected subjects develops
HAM/TSP. CD4+ T cells are the main target of infection and play a pivotal role in regulating immunity to HTLV and are
hypothesized to participate in the pathogenesis of HAM/TSP. The CD39 ectonucleotidase receptor is expressed on CD4+ T
cells and based on co-expression with CD25, marks T cells with distinct regulatory (CD39+CD25+) and effector
(CD39+CD252) function. Here, we investigated the expression of CD39 on CD4+ T cells from a cohort of HAM/TSP patients,
HTLV-1 asymptomatic carriers (AC), and matched uninfected controls. The frequency of CD39+ CD4+ T cells was increased in
HTLV-1 infected patients, regardless of clinical status. More importantly, the proportion of the immunostimulatory
CD39+CD252 CD4+ T-cell subset was significantly elevated in HAM/TSP patients as compared to AC and phenotypically had
lower levels of the immunoinhibitory receptor, PD-1. We saw no difference in the frequency of CD39+CD25+ regulatory
(Treg) cells between AC and HAM/TSP patients. However, these cells transition from being anergic to displaying a
polyfunctional cytokine response following HTLV-1 infection. CD392CD25+ T cell subsets predominantly secreted the
inflammatory cytokine IL-17. We found that HAM/TSP patients had significantly fewer numbers of IL-17 secreting CD4+ T
cells compared to uninfected controls. Taken together, we show that the expression of CD39 is upregulated on CD4+ T cells
HAM/TSP patients. This upregulation may play a role in the development of the proinflammatory milieu through pathways
both distinct and separate among the different CD39 T cell subsets. CD39 upregulation may therefore serve as a surrogate
diagnostic marker of progression and could potentially be a target for interventions to reduce the development of HAM/
TSP.
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Introduction
Human T-lymphotropic virus type 1 (HTLV-1) has been
estimated to infect 10–20 million worldwide [1]. The majority of
infected individuals remain asymptomatic carriers of this retrovi-
rus for life. However, 2% to 3% of HTLV-1-infected individuals
develop a neurodegenerative disorder characterized by a progres-
sive spastic paraparesis called HTLV-1-Associated Myelopathy/
Tropical Spastic Paraparesis (HAM/TSP) [2,3]. Other chronic
inflammatory conditions including arthritis, uveitis, polymyositis,
and Sjo¨gren syndrome have also been associated with HTLV-1
infection [4,5,6,7]. In endemic areas, 2% to 6% of seropositive
individuals develop Adult T-cell Leukemia (ATL) [8]. In the
absence of efficient treatment options that modify disease
progression and protective vaccination, understanding the causa-
tive mechanisms of disease progression is paramount to develop
preventative and treatment options.
The reasons why persons with HTLV-1 infection develop
these complications appear to be multiple and complex, and
the mechanisms for progression have not been fully deter-
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mined. Several mechanisms have been postulated to account
for disease progression to HAM/TSP such as age, gender,
transmission mode and proviral load levels [9,10,11,12,13].
Cellular immune response has been implicated in the control
of HTLV-1 infection as well as in the development of
inflammatory alterations in these patients. The viral protein
Tax is the immunodominant peptide recognized by CD8+ T
cells in patients with HTLV-1. Analyses of the role of HTLV-1
Tax-specific CD8+ T cells in the control of HTLV-1 infection
show that strong CD8+ T cytolytic activity correlates
negatively with proviral load, but it occurs regardless of
disease status [14,15]. The higher frequencies of HTLV-1-
Tax-specific IFN-c+ CD8+ T cells are positively associated with
the frequency of HTLV-1-infected cells in HAM/TSP patients
suggesting that CD8+ T cell responses may neither control
viral replication nor prevent disease progression [16,17]. Such
high frequency of HTLV-1-Tax-specific IFN-c-producing
CD8+ T cells, with low expression of inhibitory receptors in
peripheral blood and in the central nervous system appear to
contribute to the inflammatory alterations seen in HAM/TSP
patients [18,19,20,21].
Recently, the viral protein HTLV-1 basic leucine zipper
(HBZ), encoded by an anti-sense strand of the HTLV-1
provirus [22,23], may better serve as proxy for disease
progression than Tax. HBZ expression down-regulates Tax
expression [23], inhibit NF-kB classical pathway activation
and yet promotes CD4+ T-cell proliferation in transgenic mice
[24,25]. HBZ-specific CD8+ T cells, though not as frequent as
Tax-specific CD8+ T cells, appear to correlate with proviral
load and disease progression, represents a potential target for
HAM/TSP progression and provide important clues for
disease progression [26,27]. These studies, however, may only
partially account for the transition from an asymptomatic
status to the development of HAM/TSP.
HTLV-1 infects several human cell types [28,29], but primarily
CD4+ T cells [30,31]. Under specific conditions, CD4+ T cells
differentiate towards Th1, Th2, Treg and Th17 lineages
[32,33,34]. Distinct CD4+ T-cell subsets play a pivotal role on
the immune response. Regulation of HTLV-1 infection and
CD4+ T-cell subsets frequency and function may be influenced
by the expression of viral proteins Tax and HBZ that activates
promoters of several cellular genes and induces CD4+ T cell
replication [25]. Furthermore, HBZ transcription has been
reported to correlate with proviral load, inflammatory markers
and disease severity [27,35]. Higher frequencies of virus-specific
IFN-c-producing CD4+ T cells are observed in cerebrospinal
fluid (CSF) and sera of HAM/TSP patients compared to HTLV-
1 asymptomatic carriers with similar proviral load [36],
suggesting a role for CD4+ T cells in neural damage.
Understanding immune regulatory aspects and CD4+ T-cell
responses to HTLV-1 could clarify the complex pathogenesis of
HAM/TSP in the midst of strong anti-HTLV-1 immunity.
Specific CD4+ T-cell subsets play a key role in the regulation of
immune responses and inflammatory diseases [37,38] and
modulate the function of CD8+ T cells, including Tax-specific
CD8+ T cells cytolytic activity [39]. Two antagonistic subsets
involved in the pathway of tolerance and immunity, regulatory
CD4+ T cells (Treg) and Th17 cells, derives from a common
progenitor [40] and conflicting results regarding frequency and
function are found in studies of Tregs and Th17 in the
development of HAM/TSP [39,41,42,43,44,45].
The CD39 ectoenzyme can mediate immunostimulatory and
inhibitory effects by releasing adenosine through its enzymatic
activity [46]. Our previous study and those by others have shown
that expression of CD39 serves as a novel marker to identify
suppressive CD4+ T cells [47], a CD4+ T-cell subset with
immunostimulatory properties [48] and can further distinguish
between IL-17 secreting cell populations [49]. The interplay of
these T-cell subsets may reveal important aspects of HAM/TSP
pathogenesis. Furthermore, depletion of Th17 cells in the
peripheral blood and in the gut is detrimental to control of
HIV-1 infection, another retrovirus with many similarities to
HTLV-1 acquisition but with divergent clinical outcomes
[50,51,52]. It is unclear whether Th17 cells may contribute to
the immune response to HTLV-1 replication as well as to the
proinflammatory milieu seen in HAM/TSP patients.
In this study we performed an evaluation of the immunoreg-
ulatory CD4+ T-cell subsets defined by CD39 expression including
Th17 cells in patients enrolled in an HTLV-1 clinic in Sao Paulo,
Brazil. We hypothesized that changes in the CD4+ T cell
compartment would lead to alterations in T-cell functions that
may be involved in HTLV-1 disease progression. Our results
present phenotypic and functional alterations in the CD4+ T-cell
profile based on CD39 expression that could account for the
transition from an asymptomatic status to HAM/TSP, predicting
clinical disease risk and possibly track disease progression.
Materials and Methods
Ethics Statement
All human participants of this study voluntarily signed an
informed consent approved by the institutional review board of the
University of Sao Paulo (IRB #0855/08) Sao Paulo, Brazil.
Clinical investigation procedures were conducted according to the
principles expressed in the Declaration of Helsinki (http://www.
wma.net/en/30publications/10policies/b3/index.html)
Author Summary
Human T-lymphotropic virus type 1 (HTLV-1) has been
estimated to infect 10–20 million worldwide. The majority
of infected individuals are asymptomatic, however, 2% to
3% develop a neurodegenerative disorder called HTLV-1-
associated myelopathy/tropical spastic paraparesis (HAM/
TSP). The reasons why persons with HTLV-1 develop these
complications appear to be multiple and complex. Cellular
immune response has been implicated in the develop-
ment of inflammatory alterations in these patients,
however the pathogenic mechanisms for disease progres-
sion remain unclear. Regulatory CD4+ T cells (Treg) and
Th17 cells derive from a common progenitor and
conflicting results regarding frequency and function are
found in the development of HAM/TSP. The expression of
the CD39 ectoenzyme, a molecule that can mediate
immunostimulatory and inhibitory effects, is useful to
define IL-17 secreting cell populations, suppressive CD4+ T
cells and CD4+ T cells with immunostimulatory properties.
The interplay of these T-cell subsets may reveal important
aspects of HAM/TSP pathogenesis. In this study, we
performed an evaluation of the immunoregulatory CD4+
T-cell subsets defined by CD39 expression including Th17
cells. Our results present phenotypic and functional
alterations in the CD4+ T cell profile that could account
for the transition from asymptomatic status to HAM/TSP,
predicting clinical disease risk and tracking disease
progression.
CD4+ T Cell Subsets in HTLV-1 Infection
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Study Participants
We enrolled 37 patients from the HTLV-1 Outpatient Clinic at
the University of Sao Paulo, Brazil. They were invited to
participate in a longitudinal cohort of HTLV-1-infected subjects
after signing a written informed consent approved by the
University of Sao Paulo’s Institutional Review Board (#0855/
08). This cohort includes 24 asymptomatic carriers (AC) and 13
patients with neurological complications related to HTLV-1
infection denominated HTLV-1 Associated Myelopathy/Tropical
Spastic Paraparesis (HAM/TSP). The clinical status was deter-
mined based on WHO criteria for HTLV-1 associated diseases
[53]. The majority of the patients were female (67%), 17 in the
asymptomatic group and 8 HAM/TSP patients, with a median
age of 47 (Interquartile Range [IQR], 36–55) and 54 (IQR, 36–61)
years respectively.
We enrolled 19 age- and gender-matched healthy volunteers
without laboratory evidence of HTLV-1, Hepatitis B, Hepatitis C,
and HIV infections, with similar demographic characteristics as
the HTLV-1-infected participants (See Table 1).
Blood samples were obtained and processed with Ficoll-Paque
PLUS (Amersham Pharmacia Biotech, Uppsala, Sweden) gradient
centrifugation and peripheral-blood mononuclear cells (PBMC)
were isolated and cryopreserved in 10% DMSO in FBS. This
study was approved by the institutional review board and ethical
committee of the University of Sao Paulo (#0855/08).
Flow Cytometry Assessment
Cryopreserved PBMC were thawed in RPMI 1640 with 10%
FBS and washed in FACS buffer (PBS with 0.5% bovine serum
albumin, 2 mM EDTA). Phenotypic detection was performed on
106 cells by incubation with conjugated anti-CD3, CD4, CD25,
CCR4 (BD Biosciences, San Diego, CA), PD-1 (Biolegend, San
Diego, CA) and CD39 (eBioscience, San Diego, CA) for
30 minutes on ice. For intracellular staining, cells were fixed and
permeabilized prior to staining with conjugated antibodies against
FoxP3, IFN-c, IL-10, IL-2 (BD Biosciences), CTLA-4 (Immuno-
tech, Marseille, France), TNF-a (eBioscience) and IL-17 (Biole-
gend, San Diego, CA).
Proviral load and mRNA assessment. HTLV-1 proviral
DNA was extracted from PBMCs using a commercial kit (Qiagen
GmbH, Hilden Germany) following the manufacturer’s instruc-
tions. The extracted DNA was used as a template to amplify a
fragment of 158 bp from the viral tax region using previously
published primers [54]. The SYBR green real-time PCR assay was
carried out in 25 ml PCR mixture containing 106 Tris (pH 8.3;
Invitrogen, Brazil), 1.5 mM MgCl2, 0.2 mM of each primer,
0.2 mM of each dNTPs, SYBR Green (18.75 Units/r6n;
Cambrex Bio Science, Rockland, ME) and 1 unit of platinum
Taq polymerase (Invitrogen, Brazil). The amplification was
performed in the Bio-Rad iCycler iQ system using an initial
denaturation step at 95uC for 2 minutes, followed by 50 cycles of
95uC for 30 seconds, 57uC for 30 seconds, and 72uC for
30 seconds. The human housekeeping b-globin gene primers
GH20 and PC04 [55] were used as an internal control calibrator.
For each run, standard curves for the value of HTLV-1 tax were
generated from MT-2 cells of log10 dilutions (from 10
5 to 100
copies). The threshold cycle for each clinical sample was calculated
by defining the point at which the fluorescence exceeded a
threshold limit. Each sample was assayed in duplicate and the
mean of the two values was considered as the copy number of the
sample. The amount of HTLV-1 proviral load was calculated as
follows: copy number of HTLV-1 (tax) per 1,000 cells = (copy
number of HTLV-1 tax)/(copy number of b globin/2)61000 cells.
The method could detect 1 copy per 103 PBMC.
For the mRNA quantification assays, RNA was extracted using
QIAamp RNA Blood Mini Kit (Qiagen) following the manufac-
turer’s instructions and at a final 50 ml elution. The transcription
levels of Tax and HBZ and internal reference b-Actin were
measured by The Power SYBR Green RNA-to-CT 1-Step kit (Life
Technologies, Carlsbad, CA) using the StepOnePlus Real-Time
PCR System (Life Technologies). Tax and HBZ specific primers
were used to measure the respective mRNA expression level as
described previously [27]. b-actin was used as a housekeeping
control to calculate 22DDCt relative expression as previously
described [56]. This method allows measuring the relative
expression of each gene to an endogenous control, and normalizes
measurements as has been previously shown [57].
ELISPOT Assays
MAIPS4510 Elispot plates (Millipore, Danvers, MA) were
coated with anti-IL-17 or anti-IFN-c 10 mg/ml (Mabtech, Nacka
Strand, Sweden) in PBS, 50 ml/well for one hour at room
temperature. After three washes with PBS, PBMC (16105 cells/
well) and Phorbol 12-myristate 12-acetate (PMA) and ionomycin
(Ion) (Sigma, St Louis) were added, with a final volume of 200 ml/
well. Plates were incubated at 37uC in 5% CO2 for 16–20 hours.
After washing with phosphate-buffered saline (PBS) plus 0.1%
Tween 20 (PBST), biotinylated anti-IL-17 or anti-IFN-c (1 mg/
ml) (Mabtech), antibodies were added to the appropriate wells in
PBS 0.1% Tween 1% BSA (PBSTB) for 30 minutes at room
temperature. Plates were washed again three times with PBST,
and alkaline phosphatase-conjugated streptavidin (Jackson Im-
munoresearch, West Grove, PA) was added (50 ml of 1:1,000
dilution in PBSTB) and incubated for 30 min at room temper-
Table 1. Characteristics of study participants.
Uninfected (n =19) Asymptomatic carrier (n =24) HAM/TSP{ (n = 13) P value
Age, median (IQR{) 39 (29–52) 47 (36–55) 54 (36–61) NS
Gender (male/female) 6/13 7/17 5/8
CD4+ T cells, per ml (mean 6 SD**) 12176419.4 11526432.3 13056606.6 NS
CD4+ T cell percentage (mean 6 SD) 48.7567.16 54.6610.92 54.5467.80 NS
HTLV-1* proviral load, copies/103 cells (mean 6 SD) N/A 68.916124.61 249.386302.42 0.0026
{HAM/TSP: HTLV-1 associated myelopathy/tropical spastic paraparesis;
*HTLV-1: Human T Lymphotropic Virus Type 1;
{IQR: Interquartile Range, 25%–75%;
**Standard Deviation.
doi:10.1371/journal.pntd.0002028.t001
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ature. Plates were washed in PBST, incubated with blue substrate
(Vector Labs, Burlingame, CA) until spots were clearly visible,
then rinsed with tap water. When plates were dry, spots were
counted using an automated ELISPOT reader. Experiments run
in duplicate for IL-17 and IFN-c detection. Results were medium-
subtracted and normalized to 106 cells. IFN-c spots were
considered positive controls.
Statistical Analysis
Statistical analysis was performed by using GraphPad Prism
statistical software (GraphPad Software, San Diego, CA). Non-
parametric statistical tests were used throughout the analyses. The
Mann-Whitney U was used for comparison tests and the
Spearman rank test were used for correlation analyses.
Results
Higher Frequency of CD39 Expressing CD4+ T Cells
Subsets in HAM/TSP Infection
The evaluation of CD4+ T cells subsets as defined by the
expression of CD39 and CD25 has revealed novel functional
populations that redefine suppressor T cells expressing FoxP3
[47,58,59], delineate Th17 cells and identify a population of CD39
expressing T cells with immunostimulatory properties called
‘‘inducer’’ cells [48,59,60]. The expression of these markers in
HTLV-1 remains undefined.
We examined, by flow cytometry, the pattern of expression of
CD39 and CD25 in CD4+ T cells of 19 uninfected subjects, 24
HTLV-1 asymptomatic carriers and 13 HAM/TSP patients. Since
the transcription factor FoxP3 serves to define suppressor CD4+ T
cells, we first determined its distribution within the CD39+ CD4+ T
cells. Based on our gating strategy and in line with our previous study
[48], we confirmed that the distribution of FoxP3 within the CD4+
T-cell subsets using CD39 and CD25 (CD39+FoxP3+CD25+ and
CD39+FoxP3+CD252 and CD392FoxP3+CD25+) did not change
irrespective of HTLV-1 infection (data not shown).We observed that
the frequencies of CD39+CD252CD4+ T cells were significantly
higher in HAM/TSP compared to AC and uninfected subjects
(Fig. 1A,B). Similarly, the numbers of CD39+CD252CD4+ T cells
were significantly higher in HAM/TSP patients compared to
uninfected subjects (Fig. 1C). Significant higher frequencies of
CD39+CD25+CD4+ T cells were found in AC and HAM/TSP
patients compared to uninfected subjects, but the frequencies
between the two groups of HTLV-1 infected patients were not
significantly different (Fig. 1D). The numbers of CD39+CD25+CD4+
T cells were also significantly increased between HAM/TSP patients
compared to uninfected subjects (Fig. 1E). We observed no
differences in the absolute CD4+ T cell count (Fig. S2A), frequency
(Fig. S2B), and number (Fig. S2C) of CD392CD25+CD4+ T cells
between uninfected donors, AC, and HAM/TSP patients. We and
others have observed that T regulatory cells can be further defined
by the low expression of CD127 and FoxP3 [61,62]. To further
define the proportion of regulatory T cells subsets in HTLV-1
infection, we used a combination of antibodies anti-FoxP3, CD127,
and CD25. We determined that phenotypically defined regulatory
(CD127loCD25+FoxP3+) CD4+T cells were also elevated inHTLV-
1 infection using this combination of markers. (Fig. S1).
The high frequencies of CD39+CD25+CD4+ T cells in AC and
HAM/TSP subjects reinforce the idea of induced Treg differen-
tiation in HTLV-1 infection while the high frequency of
CD39+CD252 CD4+ T cells only in HAM/TSP patients may
contribute to the proinflammatory milieu seen in HAM/TSP and
represent a marker of disease progression.
Changes in the Expression of CCR4, CTLA-4 and PD-1
among the CD39 Expression CD4 T Cells in HAM/TSP
CTLA-4 is essential for regulatory T-cell suppressive function as
blockade of CTLA-4 expression abrogates Treg function [63,64].
CCR4, a chemokine receptor selectively expressed on Th2, Th17
and Tregs, has been shown to be highly expressed by HTLV-1-
infected cells [65]. Furthermore, CCR4 expressing CD25+ CD4+
T cells are functionally altered in HAM/TSP patients, producing
high levels of IFN-c [44]. In an effort to further characterize the
two immunoregulatory T cell populations defined by CD39 and
CD25 expression, we evaluated the expression of CTLA, CCR4
and PD-1 among these subsets. We observed that CD39+CD252
CD4+ T cells had the highest expression of CCR4 whereas the
CD25+CD39+ CD4+ T cells had greatest co-expression of CCR4
and CTLA-4 among uninfected subjects (Fig. 2A). In HTLV-1-
infected subjects (AC and HAM/TSP), the levels of CCR4+
CTLA4+ CD4+ T cells among the CD39+ CD25+ CD4+ T cells
significantly declined (p = 0.0159) compared to uninfected controls
(Fig. 2B).
Increased PD-1 expression has been shown to mark T cell
activation and dysfunction [66,67], but its expression has also been
used to discriminate Treg subsets [68]. We measured surface
expression of PD-1 among the different CD4+T cells and compared
the expression among the three population groups according to
CD25 and CD39 expression. We observed differential expression of
PD-1 levels with CD39+CD25+CD4+ T cells (regulatory) having
higher expression of PD-1 in HAM/TSP patients, (p= 0.0189) (Fig.
S3 A,B), whereas the CD39+CD252CD4+ T cells (inducer)
significantly expressed lower levels of PD-1 in HAM/TSP infected
patients compared to asymptomatic controls, (p= 0.0317) (Fig. S3
B). These data suggest that HTLV-1 infection alters the phenotypic
repertoire of CD4 regulatory T cells to less anergic state with those
patients with HAM/TSP and expand a population of
CD39+CD252 CD4+ T cells with lower PD-1 levels indicating a
potential for even greater T-cell activity.
Direct Association of CD39+CD252CD4+ T Cells with
HTLV-1 Proviral Load in HAM/TSP but not with AC
Subjects
High levels of HTLV-1 proviral load levels have been associated
to variable Treg frequency as well as reduced HTLV-1-specific
CD8+ T-cell lytic efficiency and frequency [14,39,54]. Because
HTLV-1 infection promotes T-cell activation and proliferation
[69] and proviral load levels are associated with CD4+ T-cell
clonal expansion [70], we wished to assess if there is an association
between proviral load and the CD39 expressing CD4+ T-cell
subsets in 24 HTLV-1 asymptomatic carriers and 13 HAM/TSP
patients. Frequency and number of CD39+CD252CD4+ T cells
from HAM/TSP patients but not from HTLV-1 asymptomatic
carriers are associated with HTLV-1 proviral load levels
(Fig. 3A,B). There was no association between proviral load and
the frequency (Fig. S4A) or numbers (Fig. S4B) of CD39+CD25+
CD4+ T cells. Overall this data suggests that CD39+CD252 CD4+
T cells may contribute to the increased rate of CD4+ T-cell
proliferation and consequently higher levels of HTLV-1 proviral
load in HAM/TSP patients.
Reduction in IL-17 Production in HAM/TSP Patients
Th17 cells have a pivotal role in many autoimmune and
inflammatory conditions, including Multiple Sclerosis (MS).
Besides, CD39+ Tregs, a T-cell subset with increased frequency
among HTLV-1-infected patients, suppress Th17 cells in healthy
individuals but are dysfunctional in MS [49], a neurodegenerative
CD4+ T Cell Subsets in HTLV-1 Infection
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Figure 1. CD25 and CD39 expression in CD4+ T cells. Compare results from HAM/TSP patients, HTLV-1 asymptomatic carriers (AC) and
uninfected subjects. The statistical difference was deemed significant using a Mann-Whitney U test analysis if p,0.05. Horizontal bars denote median
values. (A) CD39 and CD25 expression in CD4+ T cells from one representative uninfected donor, one HTLV-1-infected asymptomatic carrier and one
HAM/TSP patient. (B) Proportion of CD39+CD252CD4+ T cells. Dotted line represents higher levels of CD39+CD252 CD4+ T cells in uninfected subjects.
(C) Number of CD39+CD252CD4 T cells. (D) Proportion of CD39+CD25+CD4+ T cells. (E) Number of CD39+CD25+CD4+ T cells.
doi:10.1371/journal.pntd.0002028.g001
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disorder with some clinical similarities to HAM/TSP. Little is
known about IL-17 production in HTLV-1 infection. It has been
reported that expression of IL-17 mRNA is induced by Tax in
HTLV-1 infected T-cell lines [43] and increased in periodontal
tissue of HTLV-1-infected subjects with periodontitis [71].
However, IL-17 production from a specific CD4+ T-cell subset
is reduced among HAM/TSP patients [44].
We therefore assessed the proportion of IL-17 secreting cells
using PBMCs from 18 HTLV-1 infected patients (8 asymptomatic
carriers and 10 HAM/TSP) and 9 uninfected subjects stimulated
with PMA and ionomycin in an ELISPOT assay. We found a
significant smaller number of IL-17 secreting cells in HAM/TSP
patients compared to uninfected subjects and a trend towards a
reduced number of IL-17 secreting cells compared to HTLV-1
asymptomatic carriers (Fig. 4A, B).
We also found a significant smaller Th17/CD39+CD252 T-cell
ratio in HAM/TSP patients as compared to HTLV-1-infected
asymptomatic carriers, considering the number of IL-17 secreting
cells and the frequency or number of CD39+CD252CD4+ T cells
(Fig. S 5A). A similar reduction was found when we analyzed the
Th17/CD39+CD25+ ratio in HAM/TSP patients and compared
to HTLV-1-infected asymptomatic carriers, considering the
number of IL-17 secreting cells and the frequency or the number
of CD39+CD25+CD4+ T cells (Fig. S 5B).
Figure 2. Expression of CTLA-4 and CCR4 in CD4+ T-cell subsets based on CD39 and CD25 expression. The statistical difference was
deemed significant using a Mann-Whitney U test analysis if p,0.05. Horizontal bars denote median values. (A) CTLA-4 and CCR4 expression on CD4+
T cells from one representative uninfected donor, one HTLV-1-infected-asymptomatic carrier and one HAM/TSP patient. (B) Proportion of expression
of CTLA-4 and CCR4 in CD39+CD25+ and CD39+CD252 CD4+ T cells of uninfected donors, AC and HAM/TSP patients.
doi:10.1371/journal.pntd.0002028.g002
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Increased IFN-c, TNF-a +IL-2+ Double Positive
CD39+CD25+ CD4+ T Cells and Reduced IL-17 Expression
in HAM/TSP Patients
HAM/TSP patients appears to have CD4+ T cells that are
conditioned to produce IFN-c [36]. Conflicting data regarding IL-
17 production in HTLV-1 infected subjects and a possible role
along with IFN-c in the proinflammatory milieu observed in HAM/
TSP patients led us to investigate the production of inflammatory
cytokines of CD4+ T cells from 9 uninfected, 8 HTLV-1
asymptomatic carriers and 10 HAM/TSP patients. CD4+ T cells
subsets from HAM/TSP subjects (CD392CD25+CD4+ T cells)
showed significant reduced IL-17 levels when compared to
uninfected subjects (Fig. 5B), confirming our results from ELISPOT
assays.
Also, we found a significant increased IFN-c production among
CD39+CD25+CD4+ T cells from HAM/TSP patients compared to
HTLV-1 asymptomatic carriers and uninfected subjects (Fig. 5C).
We also observed increased levels of IFN-c in CD39+CD252CD4+
T cells in HAM/TSP subjects compared to HTLV-1 seronegative
individuals (Figure 5C). We next determined the proportion of
TNF-a and IL-2 producing CD4+ T cells in uninfected subjects,
HTLV-1 asymptomatic carriers and HAM/TSP patients (Fig. 6
A,B,C). Interestingly, we found a significant increased frequency of
TNF-a+ IL-2+ producing cells in the CD39+CD25+ CD4+ T cells
compartment among HAM/TSP patients compared to HTLV-1
asymptomatic carriers and uninfected subjects (Fig. 6D). This CD4+
T-cell subset has a suppressive phenotype and does not produce
significant amounts of IFN-c TNF-a and IL-2 in uninfected
subjects, suggesting that these immunostimulatory and/or immu-
noregulatory CD39 expressing T cell subsets may participate in the
pro-inflammatory milieu that could potentially lead to the
progression to HAM/TSP.
HBZ but not Tax Expression Associates with the
Expanded CD39+CD252CD4+ T-Cell Subset Seen in HAM/
TSP
The trans-acting viral regulatory protein Tax (Tax) gene and
the HTLV-1 basic leucine zipper (HBZ) gene, an antisense
Figure 3. Association between HTLV-1 proviral load and CD39+CD252CD4+ T cells in HAM/TSP patients. Frequency of CD39+CD252
CD4+ T cells (A) and number of CD39+CD252CD4+ T cells (B) were plotted against proviral load of AC and HAM/TSP patients. The statistical difference
was deemed significant using a two-tailed Spearman test analysis if p,0.05.
doi:10.1371/journal.pntd.0002028.g003
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transcribed mRNA promote proliferation and maintenance of
HTLV-1 infected T cells and are reported to be oncogenic factors
in ATL induction [25,27,72,73]. Both have been identified as
important targets implicated in the pathogenesis of HAM/TSP.
To assay whether increased proviral load is responsible for the
expansion of CD39+ CD4+ T-cell subsets, we evaluated protein
Tax expression by flow and gene expression of HBZ and Tax as a
proxy to determine HTLV-1 replication. HTLV-1-infected
subjects were therefore assessed for Tax expression on the CD4+
T cells subsets based on CD39 and CD25 expression. We observed
Tax expression was represented in the CD25 expressing CD4+ T
cells subsets in both CD39 and CD39 lacking cells. There was no
difference in the Tax expression representation between AC and
HAM/TSP (Fig. 7A,B). HAM/TSP patients presented with a
significantly higher level of HBZ mRNA compared to HTLV-1
asymptomatic carriers (Fig. 8A). This result is comparable to
results previously reported by Saito et al, [27]. We assessed the
relationship between HBZ transcription levels and the CD39
expressing immunoregulatory T cells. HBZ transcription levels
positively associated with both CD39+CD25+ and
CD39+CD252CD4+ T cells (Fig. 8 B,C). These data suggest that
Tax expression is absent among the CD39+CD252CD4+ T cells
that are expanded in HAM/TSP and may not be the driver for
this expansion. Our findings further suggest that HBZ is an
important viral protein that is associated with expansion of these
immunoregulatory T cells populations as disease progresses.
Discussion
In this study, we have demonstrated that CD39 serves as a
marker of the profound phenotypic and functional changes in CD4+
T cells in HTLV-1 that potentially contribute to the development of
HAM/TSP. Several important findings have been revealed from
this work. First, an increased frequency of the immunostimulatory
(CD39+CD252) CD4+ T cells in HAM/TSP patients and its
association with proviral load, a marker of disease status. These cells
retain lower levels of PD-1 reflecting a phenotypic and functional
shift in T-cell activity. Second, the reduced number of Th17 cells
combined with conversion of CD4+ T cells with suppressive
phenotype (CD39+CD25+) to those with increased IFN-c, TNF-a
and IL-2 production in patients with HAM/TSP. These data
suggest a novel role for CD39 as a useful marker and potential
mediator of the dysregulation of the CD4+ T-cell subsets in
symptomatic HTLV-1 infection. Our interpretations lead us to
conclude that these changes occur to either counterbalance the
proinflammatory effect of HTLV-1 infection or directly participate
in the immunopathology leading to HAM/TSP.
The high frequency of a T cell subset with immunostimulatory
properties [48] in HAM/TSP patients, but not in asymptomatic
carriers, suggests that CD39+CD252 CD4+ T cells contribute to the
increased CD4+ T-cell proliferation seen in HAM/TSP despite
concomitant expansion of CD4+ T cells with suppressive phenotype
(CD39+CD25+). In patients who develop HAM/TSP, such
expansion may be insufficient to control the deleterious effect of
the virus-induced inflammatory milieu. Whether HTLV-1 infection
induces an increase or reduction in regulatory CD4+ T cells
[39,42,54,74,75] remains unresolved. This may be attributable to
the different phenotypic combination of markers used to define
suppressive regulatory T cells. Defining and identifying suppressive
T cells is a major challenge in the context of autoimmunity or
infection. Activated CD4+ T cells may also express most markers
used to define Treg including FoxP3, the forkhead transcription
factor [76]. FoxP3 expression is subject to transient expression by T-
cell activation and is localized in the nucleus [77], which limits
functional analyses after intranuclear staining.
Initial studies with functional analysis of CD4+ CD25+ T cells
suggested that Tregs are dysfunctional in HAM/TSP and Tax
expression has direct inhibitory effect on FoxP3 expression and
function [42,54,75,78]. However, it has recently been demon-
strated that an increased frequency of FoxP3 expression in CD4+
T cells in HTLV-1 infection persists. One possible mechanism is
the high plasma levels of CC chemokine ligand 22 (CCL22) the
CCR4 ligand, apparently inducing FoxP3 expression [74]. Our
results support this latter hypothesis and that despite an increased
frequency of FoxP3 or T-regulatory cells (CD25+CD4+), these cells
transition from being anergic to displaying a polyfunctional
cytokine feature and may contribute to the proinflammatory
millieu leading to HAM/TSP.
Based on our findings, we propose that CD39 serves as a novel
marker to delineate the phenotype and the role of suppressive CD4+
Figure 4. Measurement of IL-17 secretion of PBMC by ELISPOT. Experiments run in duplicate. Results are medium-subtracted and normalized
to 106 cells. The statistical difference was deemed significant using a Mann-Whitney U test analysis if p,0.05. Horizontal bars indicate median values.
(A) ELISPOT data from 1 representative experiment of each group of subjects. (B) Number of IL-17 secreting cells in PBMC from 9 uninfected donors, 8
HTLV-1 asymptomatic carriers and 10 HAM/TSP patients.
doi:10.1371/journal.pntd.0002028.g004
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Figure 5. IL-17 and IFN-c production by CD4+ T cells subsets. Subsets were numbered according to CD39 and CD25 expression (A):
1 = CD39+CD25+; 2 = CD39+CD252; 3 = CD392CD25+. Graph shows median of proportion of (B) IL-17-producing CD4+ T cells and (C) IFN-c-producing
CD4+ T cells subsets after PMA and ionomycin stimulation on PBMCs from 9 uninfected, 8 HTLV-1-infected asymptomatic carriers and 10 HAM/TSP
patients. The statistical difference was deemed significant using a Mann-Whitney U test analysis if p,0.05.
doi:10.1371/journal.pntd.0002028.g005
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T cells and other CD4+ T-cell subsets in HAM/TSP patients.
CD39+CD25+CD4+ T cells from HAM/TSP produce significantly
higher levels of not only IFN-c but also TNF-a and IL-2 and more
importantly dual TNF-a+IL-2+ production within the CD39+CD25+
subset when compared to HTLV-1 asymptomatic carriers or
uninfected subjects. It is likely that these cells may constitute a
proportion of the THAM cells very elegantly described by Yamano et
al [44]. Since expression of HBZ mRNA strongly correlates with the
expansion of CD39+ expressing CD4+ T cells, HBZ may drive the
shift of these T cells subsets to a polyfunctional status.
Tax expression and proviral load levels have been used as markers
of disease progression [13,79], but results with such markers are not
consistent. Conversely, levels of HBZ mRNA were reported to
strongly correlate with disease severity [27]. The positive correlation
between HBZ mRNA levels and the frequency of both the
CD39+CD25+ and CD39+CD252 CD4+ T cell populations suggests
that HBZ is associated with expansion of these immunoregulatory
populations. Measuring CD39+CD252CD4+ T cells frequency may
be evaluated as a clinical index of disease progression to HAM/TSP
as CD4+ T cells counts is used in HIV disease progression.
Figure 6. TNF-a and IL-2 production by CD4+ T cells based on CD39 and CD25 expression. The statistical difference was deemed
significant using a Mann-Whitney U test analysis if p,0.05. Horizontal bars denote median values. TNF-a and IL-2 production by CD4+ T cells from (A)
one representative uninfected donor, (B) one HTLV-1 asymptomatic carrier and (C) one HAM/TSP. (D) Production of TNF-a and IL-2 by CD4+ T cells in
AC and HAM/TSP patients and uninfected donors based on CD39 and CD25 expression.
doi:10.1371/journal.pntd.0002028.g006
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Figure 7. Tax expression in CD4+ T cells of HTLV-1-infected subjects. Representative flow cytometry data of CD25, CD39 and Tax expression
in (A) one HTLV-1-infected asymptomatic carrier and (B) one HAM/TSP patient. Plots show Tax expression restricted to CD25+ CD4+ T cells regardless
of CD39 expression.
doi:10.1371/journal.pntd.0002028.g007
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Figure 8. Relative HBZ mRNA expression. Expression was calculated as 22DDCt using the mean of b-actin as housekeeping controls. The
statistical difference was deemed significant using a Mann-Whitney U test analysis if p,0.05. Horizontal bars denote median values. (A) Fold change
of HBZ mRNA expression in PBMCs of 4 ACs and 5 HAM/TSP patients. (B) Positive correlation between HBZ mRNA levels and frequencies of
CD39+CD252 CD4+ T cells in HTLV-1-infected patients. (C) Positive correlation between HBZ mRNA level and frequency of CD39+CD25+ CD4+ T cells in
HTLV-1-infected patients.
doi:10.1371/journal.pntd.0002028.g008
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Several inflammatory cytokines have been implicated in the
pathogenesis of HAM/TSP. IL-2, IFN-c, and TNF-a levels are
increased in HTLV-1 infection and contribute to neurological
damage in HAM/TSP patients as well as in other neuroinflamma-
tory conditions with clinical similarities to HAM/TSP such as
Multiple Sclerosis [18,21,80,81]. IL-17 also plays a pivotal role in
the pathogenesis of HIV infection [50,82] and various inflammatory
diseases [83], but conflicting results regarding frequency of Th17
and IL-17 production were described in HTLV-1 infection [43,44].
We predicted Th17 cells would be increased in HAM/TSP as in
other inflammatory diseases along with the rise in T cells with
suppressive phenotype to suppress the inflammatory process.
Surprisingly, the reduced number of Th17 cells in PBMC from
HAM/TSP patients combined with the increased frequency of
CD4+ T cells with suppressive phenotype (CD39+CD25+) resembles
results of our previous studies and from others in HIV-1 infection
[50,82,84], where we demonstrate that IL-2 mediates expansion of
CD4+ T cells expressing CD25, FoxP3, and lacking CD127, with a
negative effect over Th17 cells frequency. Lower frequency of Th17
cells combined with high frequency of CD4+ T cells with
suppressive phenotype (CD39+CD25+) results in a reduced ratio
of Th17 cells and CD39+CD25+CD4+ T cells in HAM/TSP. Thus,
the polarization of CD4+ T-cell responses towards Th1 in HAM/
TSP [85] may be the result or cause the hitherto imbalance of Th17
and suppressive CD4+ T cells seen in these patients. A thorough
analysis of Th17 cells in the CNS of HAM/TSP patients is
warranted to clarify whether this Th17 reduction is restricted to
peripheral blood or if these alterations are seen in sites where the
inflammatory process have clinical impact.
Changes in frequency of CD39 expressing CD4+ T cells may be
an important component of the alterations seen in CD4+ T-cell
responses to HTLV-1 infection. Increased frequency of CD4+ T
cells with immunostimulatory properties may be one of the missing
parts to understand the development of HAM/TSP despite of
increased frequency of CD4+ T cells with suppressive phenotype in
this condition. To determine the frequency of
CD39+CD252CD4+ T cells in HTLV-1 infection should be
considered as a proxy to disease progression. Besides, reduced
levels of IL-17 and increased IFN-c, IL-2 and TNF-a confirms the
skewed Th1 specificity of HTLV-1-related inflammatory alter-
ations and immunotherapy to restore Th17 cells may be a tool to
downregulate Th1 responses. Finding these changes in inflamma-
tory sites such as the CNS will determine if the prevention or
reversion of these alterations may represent a valuable goal for
modifying HAM/TSP clinical course.
Supporting Information
Figure S1 Dot plots of CD25, CD127 and FoxP3
expression on CD4+ T cells. (A) FoxP3 expression in CD25hi
CD127low CD4+ T cells. (B) Increased proportion of
CD25+FoxP3+CD127low CD4+ T cells in HTLV-1-asymptomatic
carriers and HAM/TSP patients compared to uninfected subjects.
(TIF)
Figure S2 (A) Number of total CD4+ T cells in uninfected
donors, HTLV-1-asymptomatic carriers and HAM/TSP
patients. (B) Proportion and (C) number of CD392CD25+ CD4+
T cells in uninfected donors, HTLV-1-asymptomatic carriers and
HAM/TSP patients.
(TIF)
Figure S3 Expression of PD-1 on CD4 T cells of
uninfected subjects, HTLV-1 asymptomatic carriers
and HAM/TSP patients based on CD39 and CD25
expression. The statistical difference was deemed significant
using a Mann-Whitney U test analysis if p,0.05. * indicates
p,0.05. Horizontal bars denote median values. (A) PD-1
expression on CD4+ T cells from one representative uninfected
donor, one HTLV-1-infected-asymptomatic carrier and one
HAM/TSP patient. (B) Proportion of expression of PD-1 in
CD39+CD25+ and CD39+CD252 CD4+ T cells of uninfected
donors, AC and HAM/TSP patients.
(TIF)
Figure S4 Correlation between HTLV-1 proviral load
and frequency and number of CD39+CD25+ CD4+ T cells
in HTLV-1-asymptomatic carriers and HAM/TSP pa-
tients. (A) Frequency of CD39+CD25+ CD4+ T cells and (B)
number of CD39+CD25+ CD4+ T cells were plotted against
proviral load of AC and HAM/TSP patients.
(TIF)
Figure S5 IL-17 production by the different subsets of
CD4+ T cells. (A) Th17/Tind cells ratio from number of IL-17
producing cells and frequency and number of CD39+CD252
CD4+ T cells of 10 HAM/TSP patients, 8 HTLV-1 asymptomatic
carriers and 9 uninfected donors. Horizontal bars indicate mean
values. (B) Th17/Treg cells ratio from number of IL-17 secreting
cells and frequency and number of CD39+CD25+CD4+ T cells of
10 HAM/TSP patients, 8 HTLV-1 asymptomatic carriers and 9
uninfected donors. The statistical differences were deemed
significant using a Mann-Whitney U test analysis if p,0.05.
Horizontal bars indicate mean values.
(TIF)
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